Erythromelalgia-like eruption in parkinsonian patients treated with bromocriptine.

In a previous report about the chronic use of bromocriptine in Parkinson disease, a distinctive cutaneous eruption was noted and termed "erythromelalgia." This eruption has occurred in 9 of 110 patients on chronic bromocriptine therapy; histopathologic examination in 3 patients showed a prominent perivascular lymphocytic infiltration and perivascular edema of the dermis, without frank vasculitis. This is a reversible unwanted effect of bromocriptine therapy.